NiKang Therapeutics: Funding, Investors & Team (Sep 2026)
NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.
NiKang Therapeutics has raised $200M across 1 funding round on record, the most recent an undisclosed round of $200M announced in May 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NiKang Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2021.
NiKang Therapeutics Funding Rounds
NiKang Therapeutics Founders and Leadership Team
Contact details for the NiKang Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →NiKang Therapeutics Funding Compared to Other Biotechnology Startups
NiKang Therapeutics' latest round of $200M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NiKang Therapeutics in Biotechnology and Wilmington
Companies Similar to NiKang Therapeutics
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Shennon Biotechnologies conducts a thorough examination and control of an enormous quantity of cells,…
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
NiKang Therapeutics Funding FAQs
What does NiKang Therapeutics do?
NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.
How much funding has NiKang Therapeutics raised?
NiKang Therapeutics has raised $200M across 1 round on record. The most recent is an undisclosed round of $200M announced in May 2021.
When did NiKang Therapeutics last raise funding?
NiKang Therapeutics' most recent funding round on record is an undisclosed round of $200M, announced in May 2021.
Who is the CEO of NiKang Therapeutics?
Zhenhai Gao is listed as CEO at NiKang Therapeutics.
Where is NiKang Therapeutics headquartered?
NiKang Therapeutics is based in Wilmington, Delaware, United States.
How many employees does NiKang Therapeutics have?
NiKang Therapeutics is in the 11-50 employee band.
How does NiKang Therapeutics' funding compare to other Biotechnology startups?
NiKang Therapeutics' latest round of $200M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's NiKang Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NiKang Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.